Premium
Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream
Author(s) -
Nagore E.,
Sevila A.,
Sanmartin O.,
BotellaEstrada R.,
Requena C.,
SerraGuillen C.,
SanchezPedreÑo P.,
Guillen C.
Publication year - 2003
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2003.05613.x
Subject(s) - xeroderma pigmentosum , imiquimod , dermatology , medicine , actinic keratoses , basal cell , basal cell carcinoma , photodermatosis , basal (medicine) , cancer research , dna , biology , genetics , dna repair , insulin
Summary Xeroderma pigmentosum (XP) is an autosomal recessive disease in which patients have a 1000‐fold increased risk of developing cutaneous neoplasms. Management of patients with XP is a difficult therapeutic challenge as they usually present with many cutaneous malignancies and continue to form skin tumours at a high rate. We describe a 19‐year‐old woman with XP who had been previously treated with many different therapeutic approaches. She had an excellent clinical response of her multiple small pigmented basal cell carcinomas and pigmentary changes using imiquimod 5% cream with only minor side‐effects.